BACKGROUND: @entity1 with @entity955 ( @entity955 ) and @entity101 are at high risk for @entity64 . Previous studies have shown elevated risk of @entity64 in @entity1 with @entity955 who have a history of @entity101 (regardless of blood pressure [BP] control) and in @entity1 with elevated BP. We assessed the association of @entity101 and BP control on clinical outcomes. METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of @entity101 requiring treatment and elevated BP (systolic >= 140 and/or diastolic >= 90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time-dependent covariate. A total of 15 916 (87.5%) @entity1 had a history of @entity101 requiring treatment. In @entity1 with elevated BP measurement at any point during the trial, the rate of @entity64 was significantly higher ( @entity101 , 1.53; 95% confidence interval [CI], 1.25-1.86), as was @entity64 ( @entity101 1.85; 95% CI, 1.26-2.72) and @entity385 ( @entity101 , 1.50; 95% CI, 1.18-1.90). Rates of major @entity548 were lower in @entity1 with a history of @entity101 ( @entity101 , 0.80; 95% CI, 0.66-0.98) and nonsignificantly lower in @entity1 with elevated BP at study entry ( @entity101 , 0.89; 95% CI, 0.77-1.03). The benefit of @entity5424 versus @entity1229 on preventing @entity64 was consistent among @entity1 with and without a history of @entity101 (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97). CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of @entity64 . These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of @entity64 in @entity1 with @entity955 . CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984.

Blood Pressure Control and Risk of @entity64 in XXXX With @entity955 : Results From the Apixaban for Reduction in @entity64 and Other Thromboembolic Events in @entity955 (ARISTOTLE) Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'stroke or systemic embolism', 'hemorrhagic stroke'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'HR'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1 :: (9606,Species) :: ['Patients']
